Evonik Cyro LLC announces the release of its new 11-page acrylic polymers brochure for the medical industry featuring its CYROLITE®, ACRYLITE® and XT® polymer brands. Written specifically for designers and engineers of medical devices and equipment, the brochure provides details on the polymers’ key properties, chemical resistance, sterilization, processability and more.
As explained in the brochure, Evonik Cyro’s newest acrylic polymer, ACRYLITE® MD acrylic polymers, are ideal for medical diagnostic applications due to their superior optical clarity, transparency and UV transmission. CYROLITE compounds and XT polymers are also outlined in the literature. Both are transparent, impact-modified, acrylic-based multipolymer compounds that are perfect for thin-walled and difficult-to-mold multicavity parts that require exceptional chemical resistance, high heat deflection temperature and impact strength.
For a free copy of Evonik Cyro’s new medical brochure , call 800-631-5384 or e-mail firstname.lastname@example.org or visit www.cyro.com and download a copy of “Acrylic Polymers for the Medical Industry“.
Evonik Cyro LLC
Evonik Cyro LLC is an Evonik Degussa Corporation group company. Headquartered in Parsippany, NJ, Evonik Cyro is a leading manufacturer of acrylic sheet and molding compounds, and bulk and performance monomers. Cyro manufactures and markets its acrylic sheet and molding compounds under the ACRYLITE® trade name in the Americas. These same products are manufactured and marketed under the PLEXIGLAS® trade name on the European, Asian, African and Australian continents.
Evonik Industries is the creative industrial group from Germany which operates in three business areas: Chemicals, Energy and Real Estate. Evonik is a global leader in specialty chemicals, an expert in power generation from hard coal and renewable energies, and one of the largest private residential real estate companies in Germany. Our strengths are creativity, specialization, continuous self-renewal, and reliability. Evonik is active in over 100 countries around the world. In its fiscal year 2008 about 41,000 employees generated sales of about Euro 15.9 billion and an operating profit (EBITDA) of more than Euro 2.2 billion.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.